2025-12-28 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the data provided.

**1) Return Rate Analysis**

*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions direct to consumers.
*   **Cumulative Return:** HIMS: 121.51%; VOO: 77.16%
*   **Divergence:** 54.34 (Relative Divergence: 34.5)

**Analysis:** HIMS has significantly outperformed the S&P 500 (VOO) in terms of cumulative return. The divergence of 54.34 indicates a substantial difference in performance. The relative divergence of 34.5 suggests that the current divergence is below the midpoint of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD  | Alpha  | Beta  | Cap(B) |
|------------|---------|------|--------|-------|--------|
| 2019-2021  | -42.0% | 74.4% | -81.0% | 0.0   | 1.5    |
| 2020-2022  | -19.0% | 78.6% | -18.0% | -0.0  | 1.5    |
| 2021-2023  | -65.0% | 78.6% | -67.0% | -0.1  | 2.0    |
| 2022-2024  | 119.0% | 79.4% | 98.0%  | -0.0  | 5.5    |
| 2023-2025  | 126.0% | 80.8% | 58.0%  | 0.1   | 7.8    |

**Analysis:**
*   **CAGR:** The company has seen volatile Compound Annual Growth Rate (CAGR), with significant negative returns in earlier periods followed by strong positive returns more recently.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant price volatility.
*   **Alpha:** The Alpha is fluctuating wildly in tandem with the CAGR, suggesting the stock's performance is significantly influenced by factors other than the market. The recent alpha indicates that the company is performing well in relative to its peers.
*   **Beta:** The Beta values are close to zero, suggesting that HIMS stock price changes are largely independent of the S&P 500 index.
*   **Cap(B):** The market capitalization has been growing, which implies the company has been able to increase its valuation over time.

**2) Recent Stock Price Fluctuations**

*   **Close:** 34.31
*   **Last-market:** Price: 34.31, Previous Close: 34.67, Change: -1.04
*   **5-day SMA:** 34.878
*   **20-day SMA:** 36.8975
*   **60-day SMA:** 43.0687

**Analysis:** The stock price has recently decreased, as indicated by the negative change in the last market data. The 5-day SMA is below the 20-day SMA, which is below the 60-day SMA, indicating a short-term downward trend.

**3) Index Indicators**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 23.10 (Oversold)
*   **PPO:** -0.1228
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (27 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** -2.7 (Short-term decline)
*   **Expected Return (%):** 31.3%

**Analysis:**

*   **MRI:** Despite recent price declines, the Market Risk Indicator recommends a high investment, suggesting confidence in the company's fundamentals and future prospects.
*   **RSI:** The low RSI value indicates the stock is currently oversold, which could signal a potential buying opportunity.
*   **PPO:** This indicates the stock may be undervalued.
*   **Hybrid Signal:** The hybrid signal recommends to invest 100% of cash in this stock.
*   **Recent Relative Divergence Change:** The negative change in relative divergence indicates a short-term downward trend compared to the S&P 500.
*   **Expected Return:** The high expected return suggests potential for significant long-term gains if the stock performs as predicted.

**4) Recent News & Significant Events**

*   **Stock Fell 4% This Week:** Indicates recent negative price pressure.
*   **Carnegie Investment Counsel Acquires Shares:** This shows institutional investment, which can be a positive sign.
*   **HIMS vs. TDOC Comparison:**  Implies HIMS is being considered as a strong player in the telehealth sector.
*   **$250 Million Share Repurchase Program:** This is generally a positive sign, indicating the company believes its stock is undervalued and is willing to invest in itself.
*   **Market Panic is Irrational:** This is an opinion piece suggesting the recent price decline may be an overreaction.
*   **Moves to Bolster Weight-Loss Biz:** Shows the company is actively working to expand and improve its services.

**Analysis:** The news is mixed. The share repurchase program and institutional investment are positive, while the stock price decline and some negative sentiment need to be considered. The company is actively trying to grow its weight loss business and is being compared to other major telehealth players, meaning the company is a good business.

**4-2) Analyst Opinions**

*   **Mean:** - (Neutral to Slightly Negative)
*   **Opinions:** 12
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00

**Analysis:** Analyst opinions are somewhat mixed, with a high average price target of $44.67 and a low of $25.00. It's important to note that there is no key/consensus rating (e.g. buy, sell, hold), so it would be essential to see where the trend has been in the past and what it would be like if we were to compare.

**5) Recent Earnings Analysis**

| 날짜       | EPS  | 매출    |
|------------|------|---------|
| 2025-11-03 | 0.07 | 0.60 B$ |
| 2025-08-04 | 0.19 | 0.54 B$ |
| 2025-05-05 | 0.22 | 0.59 B$ |
| 2024-11-04 | 0.35 | 0.40 B$ |
| 2025-11-03 | 0.35 | 0.40 B$ |

**Analysis:**

*   Revenue is growing consistently quarter-over-quarter.
*   EPS (Earnings per Share) has fluctuated.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $0.60B    | 73.80%        |
| 2025-06-30   | $0.54B    | 76.39%        |
| 2025-03-31   | $0.59B    | 73.50%        |
| 2024-12-31   | $0.48B    | 76.81%        |
| 2024-09-30   | $0.40B    | 79.16%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE       |
|--------------|-----------|-----------|
| 2025-09-30   | $0.58B    | 2.72%     |
| 2025-06-30   | $0.56B    | 7.55%     |
| 2025-03-31   | $0.55B    | 9.01%     |
| 2024-12-31   | $0.48B    | 5.46%     |
| 2024-09-30   | $0.44B    | 17.18%    |

**Analysis:**

*   **Revenue:** Consistent growth in revenue indicates increasing market demand for Hims & Hers' services.
*   **Profit Margin:** Relatively high profit margins suggest strong pricing power and efficient operations.
*   **Equity:** Growing equity indicates a strengthening financial foundation.
*   **ROE:** Return on Equity (ROE) has fluctuated, suggesting an inconsistency with how effectively the company is using investments to generate profit.

**7) Comprehensive Analysis**

Hims & Hers Health Inc. (HIMS) presents a mixed investment picture:

*   **Strengths:** The company has demonstrated significant revenue growth, high profit margins, and strong outperformance compared to the S&P 500 in terms of cumulative return. The share repurchase program signals management confidence. The Market Risk Indicator is very high which recommends investing in this stock.
*   **Weaknesses:** High volatility (MDD), recent price declines, and fluctuation of EPS are causes for concern. Recent relative divergence change suggests a short-term downward trend. ROE has also fluctuated which signals inconsistency of using equity.

*   **Overall:** HIMS appears to be a growth-oriented company in the telehealth sector with significant potential, but also carries notable risks associated with volatility and market sentiment.

**Recommendation:**

Based on the data provided, a cautious approach is warranted. While the high expected return and positive MRI suggest potential for long-term gains, the stock's volatility and recent negative price action require careful consideration. The oversold RSI suggests a potential buying opportunity, but thorough due diligence and risk assessment are essential. It may be wise to slowly increase investment at a gradual pace.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.